Targeted Micronutrient Supplementation in Diabetic Retinopathy With MTHFR Polymorphisms: Biomarker Shifts and Clinical Uncertainty

Abstract

Disturbances in one-carbon metabolism, endothelial signaling, oxidative stress, and coagulation balance are central features of diabetes-associated microvascular disease, and targeted micronutrient supplementation—including L-methylfolate, methylcobalamin, pyridoxal-5′-phosphate, antioxidants, and thiol donors—may modulate homocysteine remethylation, endothelial function, and angiogenic signaling. In a 6-month pilot study of ten patients with type 2 diabetes, mild diabetic retinopathy, and MTHFR polymorphisms, micronutrient supplementation was associated with a 23% reduction in serum homocysteine, a 47% decrease in plasma VEGF, and a 15% increase in D-dimer, biomarker shifts that are mechanistically consistent with modulation of homocysteine metabolism, oxidative stress, endothelial signaling, and fibrin turnover. Interpretation of these findings is limited by the small sample size, absence of a control group, lack of functional vascular or imaging endpoints, and incomplete coagulation assessment, as D-dimer elevations alone cannot distinguish enhanced fibrin clearance from increased thrombotic risk. While homocysteine-lowering effects were biochemically evident, they should be contextualized within prior large-scale trials demonstrating discordance between total homocysteine reduction and cardiovascular outcomes, and consideration of downstream metabolites, such as homocysteine-thiolactone, N-homocysteinylated proteins, and S-adenosylhomocysteine, may provide additional mechanistic insight. Collectively, these findings are hypothesis-generating, reflecting biochemical engagement of relevant vascular pathways rather than confirmed clinical benefit, and underscore the need for future randomized, genotype-stratified studies incorporating serial biomarker and functional assessments to establish the physiological and therapeutic relevance of targeted micronutrient interventions in diabetic microvascular disease.